Atlas Trials

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

Clinical trial NCT06747858 · RECRUITING

Trial details

NCT number
NCT06747858
Sponsor
Arcturus Therapeutics, Inc.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Cystic FibrosisCFTR Gene Mutation
Start date
2024-12-12
Primary completion
2027-06-01
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.